Rajinder
@RajinderCardiologist. Interested in all things heart failure and pulmonary hypertension. Retweets ≠︎ endorsements.
Similar User
@DrDEliaEmilia
@NunziaBorrell12
@drsonyaburgess
@MGuglin
@FranceGentMD
@adam_yousef
@i__Shrouq
@GalTsaban
@AShchendrygina
@AkhmetzhanG
@dr_mosama
@Brad_Cardiology
@MilenaAste
@Ale_MM1988
@alphonsusliew
✨Cardio-Oncology & Heart Failure: A Scientific Statement from the @HFSA‼️ #CardioOncology #HF #PositionPaper #Cancer
Redefining peri-operative myocardial infarction after cardiac surgery. Read more in #EHJ. doi.org/10.1093/eurhea… #MI #CABG #cardiotwitter @ESC_Journals @escardio
Honoured to present achievements of our #CardioOncology Centre of Excellence co-led by @DoanNgo4 at @nswparliament @NSWCVRN event. Fantastic showcase of NSW CV research. Great addresses by MPs Tim James & Jason Li, co-chairs, Parliamentary friends of heart health
📌#SacubitrilValsartan in 👥 With #HeartFailure & Deterioration in eGFR to <30 mL/min/1.73 m2 🔸Continuation of sacubitril/valsartan was associated with persistent clinical benefit & no incremental safety risk. #CardioRenal #HF
*Breaking* Top-line results positive of the highly anticipated #SOUL trial, the first powered CVOT of an oral #GLP1RA 14% reduction in MACE with oral semaglutide among 9,650 people with T2D and established CV disease and/or CKD novonordisk.com/content/nncorp…
Cardiovascular-kidney-metabolic (CKM) syndrome 🔎 Detect CKM in the early stages 👉🏼 Intervene early to 🚫 progression #MedEd #FOAMed #MedTwitter #CardioTwitter @lamcardio
Towards #Metabolomic-Based Precision Approaches for Classifying and Treating #HeartFailure Personalized approach to metabolomic phenotyping in HF jacc.org/doi/10.1016/j.… @JACCJournals @SvatiShah @KSharmaMD
📌Intra-operative & post-operative management of conduits for coronary artery bypass grafting: a clinical consensus 📝 of WG of the @escardio & @EACTS #PositionPaper #CardiacSurgery
🏥 In-hospital initiation of SGLT-2 inhibitors in patients with acute heart failure #Cardioed #Cardiology
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline For adults at high risk of CKD progression and complications, we recommend administering SGLT-2 inhibitors (strong recommendation ) bmj.com/content/387/bm…
The win ratio in cardiology trials: lessons learnt, new developments, and wise future use. Read more in #EHJ. doi.org/10.1093/eurhea… #statistical #clinicaltrial #cardiotwitter @ESC_Journals @escardio
The 4 pillars 🏛️of CKM management 🔹 RAASi 🔹 SGLT2i 🔹 GLP-1ra 🔹 nsMRA #Medtwitter #CardioTwitter #medED #FOAMed @mvaduganathan
#SimPub with #HFSA2024 in @JAMACardio from #FINEARTSHF Long-term treatment with finerenone is estimated to extend event-free survival by up to 3 years among people with HF with mildly reduced or preserved ejection fraction. ja.ma/3zCCnZl
Three #SimPub with #HFSA2024 in @CircAHA from #FINEARTSHF #CircHFSA2024 LVEF ahajournals.org/doi/abs/10.116… SGLT2i ahajournals.org/doi/abs/10.116… Age ahajournals.org/doi/10.1161/CI…
Three #SimPub with #HFSA2024 in @JACCJournals from #FINEARTSHF KCCQ jacc.org/doi/10.1016/j.… Recent Worsening HF jacc.org/doi/10.1016/j.… Time to Clinical Benefit jacc.org/doi/10.1016/j.…
Recent updates from #FINEARTSHF from virtual #HFSA2024 #LBCT sessions (🖇️below) 💥Benefits within 1 mo of initiation 💥Projected event-free survival gains by up to 3yrs 💥Pts with LVEF>60% & already treated w SGLTi consistently benefit 💥Benefits when started in any care setting
Treatment with LA may acutely ⬇️ LDL-C concentration by 75-85%. Other possible clinical benefits: include ⬇️angina, ⬆️walking distance, plaque stabilization and regression, and regression of xanthomas. ✍🏽 @EugeniaGianos @tpnedungadi @GeethaRaghuvee3 @lisahudg @Eliot_Brinton
Parameters in the assessment of pulmonary hypertension Courtesy: 2022 ESC/ERS pulm HTN Guidelines
Epicardial fat & #INOCA in women : are they associated ? Read more for the answer in this wonderful manuscript by Dr Zamani & colleagues @CedarsSinai #EHJCVI academic.oup.com/ehjcimaging/ar… @ESC_Journals @bernhard_gerber @JGrapsa @ShehabAnwer @EZancanaroMD @HanCardiomd @echo_stepbystep
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial. Read more in EHJ: academic.oup.com/eurheartj/adva… #aspirin #clopidogrel #PCI #STOPDAPT3 @escardio @ESC_Journals
United States Trends
- 1. Bengals 73,6 B posts
- 2. Chargers 61,4 B posts
- 3. McPherson 11 B posts
- 4. Herbert 32,3 B posts
- 5. Joe Burrow 18,4 B posts
- 6. #CINvsLAC 9.898 posts
- 7. #BoltUp 5.045 posts
- 8. Zac Taylor 3.967 posts
- 9. #BaddiesMidwest 18 B posts
- 10. #SNFonNBC N/A
- 11. JK Dobbins 4.100 posts
- 12. Money Mac N/A
- 13. Harbaugh 14,9 B posts
- 14. #WhoDey 1.739 posts
- 15. Chiefs 155 B posts
- 16. Ladd 5.248 posts
- 17. Tee Higgins 3.587 posts
- 18. WWIII 154 B posts
- 19. Russia 749 B posts
- 20. Josh Allen 67,2 B posts
Who to follow
-
Emilia D'Elia
@DrDEliaEmilia -
Nunzia Borrelli
@NunziaBorrell12 -
A/Prof Sonya Burgess
@drsonyaburgess -
Maya Guglin
@MGuglin -
Francesco Gentile
@FranceGentMD -
yousef alhawsawi
@adam_yousef -
Shuruq - MBS❤️
@i__Shrouq -
Gal Tsaban
@GalTsaban -
Anastasia Shchendrygina
@AShchendrygina -
Akhmetzhan Galimzhanov
@AkhmetzhanG -
Mohamed Mohamed, PhD
@dr_mosama -
Brad Wilson
@Brad_Cardiology -
Milena Aste
@MilenaAste -
Alessandro Mandurino Mirizzi
@Ale_MM1988 -
Al Liew
@alphonsusliew
Something went wrong.
Something went wrong.